Clinical spectrum of levodopa‐induced complications

The first years of Parkinson disease (PD) treatment are marked by good and sustained responses to dopaminergic therapy. With disease progression and longer exposure to levodopa (l‐dopa), patients develop a range of l‐dopa–induced complications that include motor and non‐motor symptoms. Motor complications include motor fluctuations, characterized by periods of reduced benefit from the medication, and l‐dopa–induced dyskinesia, characterized by emergence of hyperkinetic involuntary movements. Dyskinesia can occur at peak effect of l‐dopa, at the beginning and end of dose, or between doses. These motor complications are often associated with fluctuations in non‐motor symptoms, particularly fluctuations in neuropsychiatric, autonomic, and sensory symptoms. Recognizing such complications and understanding their relationship with the timing of l‐dopa doses is essential for adequate diagnosis and management. © 2014 International Parkinson and Movement Disorder Society

[1]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Weinberger,et al.  BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  G. Glass,et al.  Age of Parkinson's disease onset as a predictor for the development of dyskinesia , 2010, Movement Disorders.

[4]  G. Halliday,et al.  The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.

[5]  W. Poewe,et al.  Dystonia in parkinson's disease: Clinical and pharmacological features , 1988, Annals of neurology.

[6]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[7]  J. Jankovic,et al.  Respiratory dyskinesia in Parkinson's disease , 1986, Neurology.

[8]  C. Marsden,et al.  SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.

[9]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[10]  G. Stebbins,et al.  Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale , 2015, European journal of neurology.

[11]  A. Schrag,et al.  Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. , 2012, Journal of Parkinson's disease.

[12]  E. Melamed,et al.  Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. , 1986, Clinical neuropharmacology.

[13]  J. Volkmann,et al.  Effect of subthalamic deep brain stimulation on the function of the urinary bladder , 2004, Annals of neurology.

[14]  A. Berardelli,et al.  Onset and spread of dyskinesias and motor symptoms in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Keyser,et al.  L‐dopa‐induced respiratory disturbance in Parkinson's disease suppressed by tiapride , 1985, Neurology.

[16]  Laurence Negre-Pages,et al.  Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort , 2012, European journal of neurology.

[17]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[18]  A. Lees,et al.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD , 2008, Neurology.

[19]  T. Engber,et al.  Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. , 1989, European journal of pharmacology.

[20]  R. Sakakibara,et al.  Short‐term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing‐off phenomenon , 2003, Movement disorders : official journal of the Movement Disorder Society.

[21]  R. Pfeiffer,et al.  “On‐Off”–induced lethal hyperthermia , 1989, Movement disorders : official journal of the Movement Disorder Society.

[22]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[23]  A L Benabid,et al.  From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. , 1999, Brain : a journal of neurology.

[24]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[25]  P. LeWitt Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[26]  T. Anderson,et al.  A Pilot Study of Respiration and Swallowing Integration in Parkinson’s Disease: “On” and “Off” Levodopa , 2008, Dysphagia.

[27]  J. Turkka,et al.  Sweating dysfunction in Parkinson's disease. , 1987, European neurology.

[28]  L. Cote,et al.  Primary sensory symptoms in parkinsonism , 1976, Neurology.

[29]  A. Melo,et al.  Does levodopa improve swallowing dysfunction in Parkinson’s disease patients? , 2009, Journal of clinical pharmacy and therapeutics.

[30]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[31]  J. Marinus,et al.  Catechol‐O‐methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[32]  C. Marsden,et al.  PAINFUL PARKINSON'S DISEASE , 1986, The Lancet.

[33]  M. Mark,et al.  Drenching sweats as an off phenomenon in parkinson's disease: Treatment and relation to plasma levodopa profile , 1995, Annals of neurology.

[34]  M. Piercey,et al.  Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. , 1995, The Journal of pharmacology and experimental therapeutics.

[35]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[36]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[37]  Werner Poewe,et al.  Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[38]  T. Egberts,et al.  Novel insights in pharmacogenetics of drug response in Parkinson's disease. , 2010, Pharmacogenomics.

[39]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[40]  W R Woodward,et al.  Does an inhibitory action of levodopa contribute to motor fluctuations? , 1988, Neurology.

[41]  P. Burkhard,et al.  Levodopa‐induced ocular dyskinesia in Parkinson's disease , 2007, European journal of neurology.

[42]  J. Jankovic,et al.  Pain in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[43]  Jee-Young Lee,et al.  Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[44]  Erwan Bezard,et al.  Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies , 2001, Nature Reviews Neuroscience.

[45]  J. Nutt,et al.  “Silly Walks” in Parkinson's disease: Unusual presentation of dopaminergic‐induced dyskinesias , 2011, Movement disorders : official journal of the Movement Disorder Society.

[46]  M. Horstink,et al.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[47]  T. Chase,et al.  End‐of‐dose dystonia in Parkinson's disease , 1993, Neurology.

[48]  Mark Stacy,et al.  Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment , 2005, Movement disorders : official journal of the Movement Disorder Society.

[49]  Mark Latt,et al.  “Dancing feet dyskinesias”: A clue to parkin gene mutations , 2012, Movement disorders : official journal of the Movement Disorder Society.

[50]  A. Lees,et al.  Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[51]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[52]  Kristian Winge,et al.  Effects of dopaminergic treatment on bladder function in Parkinson's disease , 2004, Neurourology and urodynamics.

[53]  J. Jankovic,et al.  Parkinson disease subtypes. , 2014, JAMA neurology.

[54]  K. Thennarasu,et al.  Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa , 2007, Movement disorders : official journal of the Movement Disorder Society.

[55]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[56]  J. Perlmutter,et al.  Swallowing abnormalities and their response to treatment in Parkinson's disease , 1989, Neurology.

[57]  V. S. Gurfinkel,et al.  Axial kinesthesia is impaired in Parkinson's disease: Effects of levodopa , 2010, Experimental Neurology.

[58]  M. Muenter,et al.  Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.

[59]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[60]  J. Korpelainen,et al.  Sweating in Parkinsonian patients with wearing‐off , 2007, Movement disorders : official journal of the Movement Disorder Society.

[61]  N. Tuncer,et al.  The Clinical Profile of Nonmotor Fluctuations in Parkinson's Disease Patients , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[62]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[63]  P. Ashby,et al.  Stimulus-sensitive myoclonus in akinetic-rigid syndromes. , 1992, Brain : a journal of neurology.

[64]  A. Korczyn,et al.  Gender effect on time to levodopa-induced dyskinesias , 2011, Journal of Neurology.

[65]  M. Okun,et al.  Brittle Dyskinesia Following STN but not GPi Deep Brain Stimulation , 2014, Tremor and other hyperkinetic movements.

[66]  S. Leurgans,et al.  Early morning off-medication dyskinesias, dystonia, and choreic subtypes. , 2001, Archives of neurology.

[67]  T. Christmas,et al.  ROLE OF SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN VOIDING DYSFUNCTION , 1988, The Lancet.

[68]  W. Poewe,et al.  Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease , 2004, Neurology.

[69]  O. Lindvall,et al.  Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio , 2011, Movement disorders : official journal of the Movement Disorder Society.

[70]  A. Lang,et al.  The spectrum of levodopa‐related fluctuations in Parkinson's disease , 1993, Neurology.

[71]  K. Någren,et al.  Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity , 2002, PAIN.

[72]  E. Storey,et al.  Influence of Single Nucleotide Polymorphisms in COMT, MAO-A and BDNF Genes on Dyskinesias and Levodopa Use in Parkinson's Disease , 2013, Neurodegenerative Diseases.

[73]  K. Gwinn‐Hardy,et al.  Pain in Parkinson's disease , 2001, Postgraduate medicine.

[74]  R. Pfeiffer Autonomic dysfunction in Parkinson's disease , 2012, Expert review of neurotherapeutics.

[75]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[76]  C. Goetz,et al.  Akathisia in Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[77]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[78]  P. Thompson,et al.  Disordered respiration as a levodopa‐induced dyskinesia in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[79]  F. Raudino Non motor off in Parkinson's disease , 2001, Acta neurologica Scandinavica.

[80]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[81]  David Borsook,et al.  Noxious hot and cold stimulation produce common patterns of brain activation in humans: a functional magnetic resonance imaging study , 2000, Neuroscience Letters.

[82]  A. Lang,et al.  Akathisia in idiopahic Parkinson's disease , 1987, Neurology.

[83]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[84]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.

[85]  L. Cote,et al.  Painful dystonic spasms in Parkinson's disease. , 1984, Advances in neurology.

[86]  E. Melamed Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. , 1979, Archives of neurology.

[87]  Parkinsonian Patients and Poor Awareness of Dyskinesias , 2014, Front. Neurol..

[88]  J. Perret,et al.  DOES O‐METHYL‐DOPA PLAY A ROLE IN LEVODOPA‐INDUCED DYSKINESIAS? , 1977, Acta neurologica Scandinavica.

[89]  D. Goldstein,et al.  Autonomic dysfunction in Parkinson disease. , 2013, Handbook of clinical neurology.

[90]  O. Rascol,et al.  Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. , 2013, Parkinsonism & related disorders.

[91]  D. Maltête,et al.  Acute genital pain during non‐motor fluctuations improved by apomorphine , 2013, Movement disorders : official journal of the Movement Disorder Society.

[92]  C. Goetz,et al.  Levodopa-induced myoclonus. , 1975, Archives of neurology.

[93]  A. Rajput,et al.  Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease , 2013 .

[94]  N. Van Blercom,et al.  Levodopa‐induced ocular dyskinesias in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[95]  Andrew J Lees,et al.  Validation of the MDS‐UPDRS Part I for nonmotor symptoms in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[96]  N. Quinn Classification of fluctuations in patients with Parkinson's disease , 1998, Neurology.

[97]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[98]  John C. Rothwell,et al.  Pathophysiology of somatosensory abnormalities in Parkinson disease , 2013, Nature Reviews Neurology.

[99]  S. Fahn “On‐off” phenomenon with levodopa therapy in parkinsonism , 1974, Neurology.

[100]  A. Lang,et al.  Akathisia in idiopathic Parkinson's disease. , 1987, Neurology.

[101]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.

[102]  R. Carasso,et al.  Respiratory Muscle Performance and the Perception of Dyspnea in Parkinson's Disease , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[103]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[104]  Z. Katsarou,et al.  Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s disease , 2011, International journal of clinical practice.

[105]  M. Rich,et al.  Respiratory dyskinesia. An underrecognized phenomenon. , 1994, Chest.

[106]  P. Boon,et al.  The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease , 2007, Clinical Neurology and Neurosurgery.

[107]  J. Crameri,et al.  Response of parkinsonian swallowing dysfunction to dopaminergic stimulation , 1997, Journal of neurology, neurosurgery, and psychiatry.

[108]  M. Swash,et al.  Anal sphincter dysfunction in Parkinson's disease. , 1989, Archives of neurology.

[109]  A. Berardelli,et al.  Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: clinical features and mechanisms. , 2013, Parkinsonism & related disorders.

[110]  Marianna Amboni,et al.  The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.

[111]  M. Hutz,et al.  Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson’s disease patients , 2013, The Pharmacogenomics Journal.

[112]  P. Zhuang,et al.  Stimulation-Induced Dyskinesia in the Early Stage after Subthalamic Deep Brain Stimulation , 2009, Stereotactic and Functional Neurosurgery.

[113]  P. Sonsalla,et al.  Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug‐induced chorea , 1991, Annals of neurology.

[114]  E. Lane Clinical and experimental experiences of graft-induced dyskinesia. , 2011, International review of neurobiology.

[115]  A. Miller,et al.  Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. , 1990, The American journal of medicine.

[116]  Kailash P Bhatia,et al.  The expanding universe of disorders of the basal ganglia , 2014, The Lancet.

[117]  G C Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[118]  R. Duvoisin Variations in the "on-off" phenomenon. , 1974, Advances in neurology.

[119]  M. Yahr,et al.  Ocular dyskinesias in patients with Parkinson's disease treated with levodopa , 1977, Annals of neurology.

[120]  Duvoisin Rc Variations in the "on-off" phenomenon. , 1974 .

[121]  S. Wessely,et al.  The Parkinson fatigue scale. , 2005, Parkinsonism & related disorders.

[122]  A. Prince,et al.  Letter: Hepanosticon in screening for HBsAg. , 1975, Lancet.

[123]  A. Williams,et al.  Stridor during dystonic phases of Parkinson's disease. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[124]  C. Marsden,et al.  Micturition disturbance in Parkinson's disease. , 1985, British journal of urology.

[125]  K. Ray Chaudhuri,et al.  Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected , 2014, Practical Neurology.

[126]  J. Sage,et al.  Nonmotor fluctuations in patients with Parkinson's disease , 1996, Neurology.